Drug intelligence / Profile preview

Jumtab

Development stage: Unknown
Lead developer: Biogen
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

Jumtab is a pharmaceutical drug that is a brand of interferon beta-1a, a cytokine used to treat relapsing forms of multiple sclerosis (MS). It functions by modulating the immune system, balancing pro- and anti-inflammatory agents in the brain, reducing the migration of inflammatory cells across the blood-brain barrier, and decreasing neuronal inflammation. It is administered intramuscularly. Biogen is involved in its development.

Brand names: Jumtab

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on Jumtab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jumtab.

Explore the full profile